The objective of this study is to evaluate abicipar pegol for safety and treatment effects in participants with neovascular age-related macular degeneration (AMD).

Start Date25 May 2018

Sponsor / Collaborator

Allergan Plc

NCT02462486 / CompletedPhase 3

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA Study)

This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.

Start Date25 Jun 2015

Sponsor / Collaborator

Allergan Plc

NCT02462928 / CompletedPhase 3

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (CEDAR Study)

This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.

Start Date25 Jun 2015

Sponsor / Collaborator

Allergan Plc

100 Clinical Results associated with Abicipar pegol

100 Translational Medicine associated with Abicipar pegol

100 Patents (Medical) associated with Abicipar pegol

Literatures (Medical) associated with Abicipar pegol

01 Jul 2023·Archivos de la Sociedad Espanola de Oftalmologia

Differential diagnosis of endophthalmitis after intravitreal drug injection for age related macular degeneration: sterile vs. infectious

Review

Author: Gallego-Pinazo, R ; Dolz-Marco, R ; Montolío-Marzo, E ; Montolío-Marzo, S ; Vidal-Oliver, L

The recent release of brolucizumab and the development of new antiangiogenic molecules as abicipar pegol has increased the interest towards inflammatory complications after intravitreal drug injection. Those drugs are associated to a higher rate of inflammatory adverse events compared to classic drugs. In this context it is essential to differentiate between sterile and infectious cases for a fast and effective treatment. The clinical similarities between infectious and sterile cases, the high rate of culture negative patients and the heterogeneity in the terminology used are obstacles for a correct diagnosis and report of these complications. Sterile cases appear early after the injection, before 48 h; or 20 days after in brolucizumab-related vasculitis cases. Infectious cases show up around the third day after injection and up to a week after it. A severe visual impairment, severe pain, severe hyperemia, hypopyon and a more severe intraocular inflammatory process are signs of a likely infectious origin. If the cause of the inflammation is uncertain we must follow up the patient closely or "tap and inject" antimicrobial agents in order to prevent the eventual complications of an infectious endophthalmitis. On the other hand, sterile endophthalmitis might be observed in mild cases or treated with steroids according to the severity of the inflammation.

01 Jan 2023·Vestnik oftalmologii

[Modern trends in anti-VEGF therapy for age-related macular degeneration].

Article

Author: Alkharki, L ; Budzinskaya, M V ; Plyukhova, A A

Age-related macular degeneration (AMD) develops in people aged 50 years and older, its pathogenesis involves progressive destruction of the retinal pigment epithelium and Bruch's membrane. There are eight currently known anti-VEGF drugs for treating the neovascular form of AMD, four of them have already been registered and are used in clinical practice. The first registered drug was pegaptanib, which selectively blocks VEGF₁₆₅. Subsequently, a molecule with a similar mechanism of action was developed and named ranibizumab, which is a humanized monoclonal Fab fragment; it was specifically designed for ophthalmology. Its advantage over pegaptanib was neutralization of all active VEGF-A isoforms. Aflibercept and conbercept are recombinant fusion proteins that act as soluble decoy receptors for VEGF family proteins. Phase III data from the VIEW 1 and 2 studies showed that intraocular injections (IVI) of aflibercept every 1 or 2 months for a year resulted in comparable functional outcomes to monthly IVI of ranibizumab for one year. The next molecule for anti-VEGF therapy that showed effectiveness was brolucizumab - a single-chain fragment of a humanized antibody that binds with high affinity to various VEGF-A isoforms. Simultaneously with studying brolucizumab, another study was conducted involving Abicipar pegol, but that drug showed a high rate of complications. The latest drug registered for the treatment of neovascular AMD is faricimab. The molecule of this drug is a humanized immunoglobulin G antibody that acts on two key points of angiogenesis: VEGF-A and angiopoietin-2 (Ang-2). Thus, the strategy for advancing anti-VEGF therapy lies in the development of molecules with greater efficiency (better effect on newly formed vessels leading to resorption of exudate in the retina, under the neuroepithelium and under the retinal pigment epithelium), which allows not just to preserve vision, but to also significantly improve it when there is no macular atrophy.

01 Jan 2023·Clinical ophthalmology (Auckland, N.Z.)

Impact of Modifying Abicipar Manufacturing Process in Patients with Neovascular Age-Related Macular Degeneration: MAPLE Study Results.

Author: Callanan, David ; Le, Grace ; Li, Xiao-Yan ; Attar, Mayssa ; Mehta, Shraddha ; Hassan, Tarek ; Khanani, Arshad M ; Badger, Hanh ; Seal, Jennifer ; Eichenbaum, David ; Maturi, Raj K ; Khurana, Rahul N ; Wykoff, Charles C ; Patel, Sunil

Purpose:

To evaluate the impact of modifying the abicipar pegol (abicipar) manufacturing process on the safety and treatment effect of abicipar in patients with neovascular age-related macular degeneration (nAMD).

Methods:

A new process for manufacturing abicipar was developed to reduce host cell impurities. In a prospective, Phase 2, multicenter, open-label, 28-week clinical trial, patients (n=123) with active nAMD received intravitreal injections of abicipar 2 mg at baseline (day 1) and weeks 4, 8, 16, and 24. Outcome measures included proportion of patients with stable vision (<15-letter loss from baseline; primary endpoint), change from baseline in best-corrected visual acuity (BCVA) and central retinal thickness (CRT), and adverse events.

Results:

Overall, 8.9% (11/123) of patients experienced intraocular inflammation (IOI) and discontinued treatment. IOI cases were assessed as mild (2.4% [3/123]), moderate (4.9% [6/123]), or severe (1.6% [2/123]) and resolved with steroid treatment. Visual acuity in most patients with IOI (8 of 11) recovered to baseline BCVA or better by study end. No cases of endophthalmitis or retinal vasculitis were reported. Stable vision was maintained for ≥95.9% (≥118/123) of patients at all study visits. At week 28, treatment-naïve patients showed a greater mean improvement from baseline in BCVA compared with previously treated patients (4.4 vs 1.8 letters) and a larger mean CRT reduction from baseline (98.5 vs 45.5 μm).

Conclusion:

Abicipar produced using a modified manufacturing process showed a moderately lower incidence and severity of IOI compared with Phase 3 abicipar studies. Beneficial effects of treatment were demonstrated.

News (Medical) associated with Abicipar pegol

27 May 2023

·pipelinereview.com

Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting

MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation MP0317 demonstrates a favorable safety profile across Q3W and Q1W regimens, including the highest dose tested, 10mg/kg (Q3W) Present data support planning of future combination studies with potential partners ZURICH-SCHLIEREN, Switzerland and CONCORD, MA, USA I May 25, 2023 I Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present additional positive data from the ongoing Phase 1 study of MP0317, a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment by anchoring to fibroblast activation protein (FAP), at the 2023 ASCO (American Society of Clinical Oncology) Annual Meeting, held June 2–6 in Chicago, Illinois. The data demonstrate that MP0317 shows evidence of tumor-localized CD40 activation (analyses in paired tumor biopsies). The detection of MP0317 in tumors positively correlated with immune activation when comparing high vs. low doses of MP0317. This detection was associated with a statistically significant CD40-mediated increase of antigen-presenting cells and interferon γ signature. Furthermore, MP0317 has demonstrated a favorable safety profile. The current data support planning of future combination studies. “These positive data continue to demonstrate that MP0317’s unique mechanism of action has the potential to overcome the limitations of existing therapies that target CD40 by activating only in the tumor microenvironment and therefore avoid systemic toxicities seen by other treatments,” said Nicolas Leupin, MD, Ph.D., Chief Medical Officer of Molecular Partners. “MP0317 encapsulates the advantages we believe we can achieve through our DARPin platform: to design candidates to overcome biological challenges that other drug classes like antibodies cannot address. These data of the ongoing study will further support the advancement of MP0317 into later-stage clinical research with partners and highlight the potential of MP0317 for evaluation in combination settings.” “Clinical data from 36 patients with advanced solid tumors, dosed across 8 dose levels, confirms that the tumor-FAP-targeted CD40 agonist MP0317 is safe and well tolerated with limited systemic inflammation compared to other CD40 agonists,” said Dr Carlos Gomez-Roca, Head of the Early Phase & Clinical Research Unit at IUCT-Oncopole Claudius Regaud at Toulouse, France, and investigator on the study. “The analysis of paired pre- and on treatment tumor biopsies as well as peripheral biomarkers provides evidence of target occupancy and pharmacodynamic modulation in the tumor microenvironment, consistent with tumor localised CD40 activation. The current data enables further evaluation of MP0317 in combination.” This ongoing first-in-human Phase 1, open-label, dose-escalation study assesses the safety and tolerability as well as pharmacokinetics/pharmacodynamics and antitumor activity of MP0317 monotherapy in patients with refractory/relapsed solid tumors known to express FAP and CD40 (NCT05098405 ) . To date, the 36 patients enrolled in the Netherlands and France across eight dosing cohorts received MP0317 at doses of 0.03–10 mg/kg in every-3-weeks [q3w] and weekly [q1w] schedules (data cut-off 02 May 2023). MP0317 monotherapy was seen to result in tumor-localized CD40 activation: biomarker data confirmed presence of MP0317 in the tumors of patients with evaluable pre- and on-treatment biopsies as of the cutoff date. This detection of MP0317 in tumors positively correlates when comparing high vs. low doses of MP0317 and was associated with a statistically significant CD40-mediated increase of antigen-presenting cells as well as interferon γ production within the tumor microenvironment. To date, one patient achieved an unconfirmed partial response and stable disease was observed in 5 additional patients. The observed safety profile of MP0317 monotherapy to date is favorable. A dose-limiting toxicity was reported in one patient (transient asymptomatic Grade 3 elevation of liver enzymes), at the highest planned MP0317 dose of 10 mg/kg administered q3w. The positive results of this ongoing Phase 1 study in patients with refractory/relapsed tumors support continued clinical evaluation of MP0317 and potential investigation in combination studies. The study continues to enroll one more cohort (q1w). For further information please see clinicaltrials.gov (NCT05098405). The details of the poster presenting these results from the ongoing Phase 1 study at the ASCO 2023 Annual Meeting can be found below. The poster will be made available on Molecular Partners' website after the presentation. Title: Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors Poster Session: Developmental Therapeutics—Immunotherapy Abstract number: 2584 Poster number: 426 Location & Timing: Hall A; June 3, 2023; 8:00–11:00am CDT Authors & Affiliations: C Gomez-Roca 1 , N Steeghs 2 , E Gort 3 , H De Winter 4 , E Fernandez 4 , V Stavropoulou 4 , N Stojcheva 4 , P Baverel 4 , J Krieg 4 , K Ioannou 4 , A Florescu 4 , P Mossi 4 , L Hoenig 4 , B Baud-Berthier 4 , V Kirkin 4 , A Goubier 4 , P Legenne 4 , P Cassier 5 About MP0317 MP0317 targets both the FAP and the immunostimulatory protein CD40 to enable tumor-localized immune activation. Through this proposed mechanism of action, MP0317 is designed to activate immune cells specifically within the tumor microenvironment, potentially delivering greater efficacy with fewer side effects compared to systemic CD40-targeting therapies. About Molecular Partners AG Molecular Partners AG is a clinical-stage biotech company developing DARPin (designed ankyrin repeat protein) therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of oncology and virology and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com ; Find us on Twitter - @MolecularPrtnrs 1 Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France 2 The Netherlands Cancer Institute, Amsterdam, the Netherlands 3 UMC Utrecht, Utrecht, the Netherlands 4 Molecular Partners AG, Schlieren-Zurich, Switzerland; 5 Centre Léon Bérard, Lyon, France SOURCE: Molecular Partners

Phase 1ASCOClinical ResultImmunotherapy

28 Feb 2023

·pipelinereview.com

Molecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy Platform

Proprietary Radio DARPin Therapy Platform designed to deliver high amount of radioactivity to the tumor while maintaining low accumulation in other tissues Data reveal engineering approach to significantly reduce kidney accumulation of DARPin-based radiotherapeutic candidates to potentially expand therapeutic window of the class Several in-house and Novartis-partnered DARPin-based radiotherapeutic programs in indications with high unmet medical need currently underway Data to be presented at the 12th International Symposium on Targeted Alpha Therapy (TAT 12) ZURICH-SCHLIEREN, Switzerland and CONCORD, MA, USA I February 28, 2023 I Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the presentation of new preclinical data from the company’s Radio DARPin Therapy Platform at the 12 th International Symposium on Targeted Alpha Therapy (TAT 12) in Cape Town, South Africa on February 28, 2023. The platform represents a unique and innovative delivery system for radioactive payloads to solid tumors, an approach with proven potential but with technological limitations that DARPins may address. “These initial data demonstrate the potential of our approach to deliver high amounts of radioactivity to the tumor while overcoming the challenge of small, protein-based delivery vectors accumulating in the kidney. The therapeutic opportunity emerging from this approach is to enhance both safety and efficacy as higher dosages of radioactivity will selectively accumulate at the tumor site,” said Daniel Steiner, Ph.D., Senior Vice President of Research at Molecular Partners. “Following our recent selection of DLL3 as the first disclosed target and the progression of several other discovery-stage programs underway, both in-house and with our partner Novartis, we look forward to continuing to expand the technological capabilities of our Radio DARPin Therapy Platform.” The presented data demonstrate Molecular Partners’ ability to engineer the surface of DARPin-based radiotherapeutics to dramatically reduce its accumulation in the kidney, a historical challenge with small protein-based delivery vectors. In preclinical models, the surface engineering did not affect tumor uptake or uptake in other healthy organs and combination with another kidney reduction strategy provided a cumulative benefit. These results will be presented at TAT12 in a poster, the details of which can be found below. The poster will be made available on Molecular Partners website, after the presentation. Poster: “DARPins as Powerful Targeting Agents for Radioligand Therapeutics” Number: 33 Timing: February 28, 2023 Presenter: Daniel Steiner, Ph.D., Senior Vice President of Oncology Research About Molecular Partners AG Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of oncology and infectious disease and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com ; Find us on Twitter - @MolecularPrtnrs SOURCE: Molecular Partners

Radiation Therapy

16 Jan 2023

·pipelinereview.com

Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid Leukemia

ZURICH-SCHLIEREN, Switzerland and CONCORD, MA, USA I January 16, 2023 I Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, announced today that the first patient has been treated in a Phase 1 first-in-human study evaluating the safety, tolerability, and efficacy of MP0533, the company’s candidate for acute myeloid leukemia (AML). MP0533 is designed to focus an immune attack against AML in a new way that preferentially spares healthy cells, which has been a historic challenge for CD3-targeting therapeutics. “AML is a notoriously difficult cancer to treat, in large part due to the overlapping targets which are expressed on both healthy, and leukemic cells. Our team has worked relentlessly over the past 3 years to develop a molecule intended to target these cancerous cells, while avoiding healthy cells. MP0533’s mechanism represents a new level of precision targeting in complex cancers that may permit greater use of the immunostimulatory power of CD3,” said Nicolas Leupin, M.D., Ph.D., Chief Medical Officer of Molecular Partners. “We are grateful to our team and our collaborators for reaching this milestone and look forward to learning more about the potential of MP0533 to help these patients.” MP0533 simultaneously targets three surface proteins, CD33, CD123, and CD70, that are vastly more likely to appear together on AML blast cells and leukemic stem cells over healthy cells. It also targets an immunostimulatory protein, CD3, on cytotoxic T cells, which will only activate when at least two of the surface proteins are bound. This novel mechanism is intended to greatly favor CD3 activation in proximity to leukemic stem cells rather than the systemic activation seen in previous CD3-based T cell engagers. The Phase 1 open-label dose escalation study will enroll patients with relapsed/refractory AML and higher-risk myelodysplastic syndromes (MDS). It is designed to assess the safety, tolerability, and efficacy of MP0533 in addition to a range of secondary endpoints, such as the effect on LSCs, pharmacodynamics, T-cell activation, and cytokine release. Between 20-45 patients are expected to be enrolled across five sites in Switzerland and the Netherlands in collaboration with certain sites within the HOVON cooperative group. Additional clinical sites are planned as well. MP0533 preclinical data demonstrates its greatly increased avidity for cells expressing two or three of the tumor associated antigens (TAAs) compared to cells expressing a single TAA. MP0533 also demonstrated an ability to induce T cell activation and killing of AML cells in samples from newly diagnosed and previously treated patients. The research also showed that MP0533 was able to directly target and kill LSCs while sparing a variety of healthy cells including hematopoietic stem cells, endothelial cells, and T cells. About Molecular Partners’ Oncology Product Candidates Molecular Partners is developing several candidates designed to activate the immune system to fight cancer while reducing damage to healthy cells. These candidates use multiple novel DARPin technologies potentially applicable against a wide range of tumor types, including DARPin candidates with the ability to restrict immune activation to the tumor microenvironment, the ability to target intracellular disease-associated proteins, and multiple novel control mechanisms for immune activation designed to direct immune attack to the right cells, at the right place, and at the right time. These capabilities can be combined during candidate design through the inherent modularity of the DARPin platform, to provide precise control over immune activation and potentially enable more effective cancer therapies. About Molecular Partners AG Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology, and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com ; Find us on Twitter - @MolecularPrtnrs SOURCE: Molecular Partners

Phase 1PROTACs

100 Deals associated with Abicipar pegol

External Link

KEGG	Wiki	ATC	Drug Bank
D11517	-	-	DB12258

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Wet Macular Degeneration	NDA/BLA	EU	-	-
Age Related Macular Degeneration	Phase 3	US	Allergan Plc	25 Jun 2015
Age Related Macular Degeneration	Phase 3	JP	Allergan Plc	25 Jun 2015
Age Related Macular Degeneration	Phase 3	AR	Allergan Plc	25 Jun 2015
Age Related Macular Degeneration	Phase 3	AU	Allergan Plc	25 Jun 2015
Age Related Macular Degeneration	Phase 3	AT	Allergan Plc	25 Jun 2015
Age Related Macular Degeneration	Phase 3	BR	Allergan Plc	25 Jun 2015
Age Related Macular Degeneration	Phase 3	CA	Allergan Plc	25 Jun 2015
Age Related Macular Degeneration	Phase 3	CL	Allergan Plc	25 Jun 2015
Age Related Macular Degeneration	Phase 3	CO	Allergan Plc	25 Jun 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03539549 (CTgov)	Phase 2	Wet age-related macular degeneration	124	Abicipar pegol	udbshgdhae(xqohzxsmfz) = eklgdmprig xuzkiesxtf (yznoixaeov, kgmooaisjo - vqkxmqwgrc) View more	-	03 Aug 2020
NCT02462486 (SEQUOIA, CTgov)	Phase 3	Age Related Macular Degeneration	949	Sham Procedure+Abicipar Pegol (Abicipar Pegol 2 mg (2Q8))	orgbwvxqok(fzxoxrqjzf) = baojkrtkkz uvuwsdschh (afrimtsthk, icpkoqgkgv - qipfikbzul) View more	-	30 Jul 2020
				Sham Procedure+Abicipar Pegol (Abicipar Pegol 2 mg (2Q12))	orgbwvxqok(fzxoxrqjzf) = kuoasjjauj uvuwsdschh (afrimtsthk, wpylzjcktn - ucbxlfcswg) View more
NCT02462928 (CEDAR, CTgov)	Phase 3	Age Related Macular Degeneration	939	Sham Procedure+Abicipar Pegol (Abicipar Pegol 2 mg (2Q8))	wycabuhgnq(lovesmxhbh) = xoomuzcmdb oozyajjnpt (rciqltcbvo, esbmaqlebo - gucfvwfuiz) View more	-	28 Jul 2020
				Sham Procedure+Abicipar Pegol (Abicipar Pegol 2 mg (2Q12))	wycabuhgnq(lovesmxhbh) = jehdktblfl oozyajjnpt (rciqltcbvo, rhwhbzlqxb - isdwkcjtas) View more
SEQUOIA, CEDAR (ARVO2019)	Phase 3	Wet age-related macular degeneration	-	abicipar 2q8	ahvsnevqcq(zlzhpurlka) = ycrrqctcxy zctsfmjgti (alkmjpliij )	Positive	01 Jul 2019
				abicipar 2q12	ahvsnevqcq(zlzhpurlka) = jhczxdvmtf zctsfmjgti (alkmjpliij )
NCT02181504 (CTgov)	Phase 2	Wet age-related macular degeneration	25	sham procedure+abicipar pegol (Abicipar Pegol 2 mg)	rfyscjqwbf(bniksimcju) = ybrigacifk ucweszayko (oevaifbqet, stwzazkoem - xswwbxkzdm) View more	-	25 Apr 2017
				sham procedure+abicipar pegol (Abicipar Pegol 1 mg)	rfyscjqwbf(bniksimcju) = pfkfsecivm ucweszayko (oevaifbqet, ywebfswjqz - jjpralspjk) View more
NCT02181517 (CTgov)	Phase 2	Wet age-related macular degeneration	25	sham procedure+abicipar pegol (Abicipar Pegol 1 mg)	ohldocncet(insohhsaij) = gzdqjcgahk ukekbyrjlq (ryqepkiomh, uknhuxvaqx - kyomsfgmcs) View more	-	05 Apr 2016
				sham procedure+abicipar pegol (Abicipar Pegol 2 mg)	ohldocncet(insohhsaij) = xwkdjqeotu ukekbyrjlq (ryqepkiomh, vvkczhricp - qrvxpnaojs) View more
NCT01086761 (Pubmed \| Am J Ophthalmol)	Phase 1/2	Wet age-related macular degeneration	32	MP0112 1.0 or 2.0 mg	btkkkotarm(imldxogvee) = because of a case of endophthalmitis in the 2.0 mg cohort lrwkfourmc (kfjmjeenac ) View more	-	01 Oct 2014
NCT01042678 (CTgov)	Phase 1	Diabetic macular oedema	18	MP0112 (MP0112 (0.04 mg))	srdfgrpnyy(acamrmluws) = ogcayeeoew tdvjvgfqqz (ihgtifukdz, wnsuiujcmy - wmclmagxvv) View more	-	13 May 2014
				MP0112 (MP0112 (0.15 mg))	srdfgrpnyy(acamrmluws) = esckdkngir tdvjvgfqqz (ihgtifukdz, nxgyynpgny - auvwevifjl) View more
NCT01086761 (Phase I MP0112 Wet AMD Study, CTgov)	Phase 1	Wet age-related macular degeneration	32	MP0112 (MP0112 (0.04 mg))	xhglzzrorq(skqotocnib) = mcuarhljye kiphgugvyk (llttyeeonm, rxegamrjzz - klczmzdsen) View more	-	12 May 2014
				MP0112 (MP0112 (0.15 mg))	xhglzzrorq(skqotocnib) = nbzvskntdb kiphgugvyk (llttyeeonm, gfujgfzoar - nvdobfyyhq) View more
NCT01042678 (ARVO2011)	Phase 1/2	Diabetic macular oedema	-	DARPin® MP0112	quwfudgwik(bqqoronwkc) = The most frequent adverse event was a transient, sterile inflammation that resolved without visual consequences iosdhwwauo (axjclwidkk )	-	01 Apr 2011

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis